Congress and the Pentagon are investing in the emerging biotechnology field as a critical driver of national security under the annual defense policy legislation President Donald Trump signed in December.
Biotechnology—the design and engineering of biological systems—is the “next battlefield” in the competition between the US and China, according to a commission set up by Congress to advance the US’s capability in the field.
Coupled with artificial intelligence, biotech will transform everything from national defense to how Americans eat and receive care, according to the National Security Commission on Emerging Biotechnology.
The National Defense Authorization Act for fiscal 2026 requires ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.